Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 20/20 | 0.57 |
| ▸ | RPTOR | Q8N122 | 8/20 | 0.57 |
| ▸ | MLST8 | Q9BVC4 | 8/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.55 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.51 |
| ▸ | RICTOR | Q6R327 | 1/20 | 0.50 |
| ▸ | MAPKAP1 | Q9BPZ7 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7936331 | 1.00 | MTOR (0.57) | MTORRPTORMLST8CYP3A4PIK3CA | |
| SCHEMBL2632744 | 0.89 | MTOR (0.73) | MTORRPTORMLST8CYP3A4PIK3CA | |
| SCHEMBL1833013 | 0.89 | MTOR (0.73) | MTORRPTORMLST8CYP3A4PIK3CA | |
| SCHEMBL1830673 | 0.89 | MTOR (0.73) | MTORRPTORMLST8CYP3A4PIK3CA | |
| SCHEMBL2625439 | 0.89 | MTOR (0.73) | MTORRPTORMLST8CYP3A4PIK3CA | |
| SCHEMBL1833060 | 0.89 | MTOR (0.73) | MTORRPTORMLST8CYP3A4PIK3CA | |
| SCHEMBL7943384 | 0.87 | MTOR (0.56) | MTORRPTORMLST8CYP3A4PIK3CA | |
| SCHEMBL7945347 | 0.87 | MTOR (0.56) | MTORRPTORMLST8CYP3A4PIK3CA | |
| SCHEMBL7942555 | 0.83 | MTOR (0.54) | MTORRPTORMLST8CYP3A4PIK3CA | |
| SCHEMBL7942557 | 0.83 | MTOR (0.54) | MTORRPTORMLST8CYP3A4PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010014939-A1 | PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | GENENTECH, INC. (US) | 2010-02-04 | — | — | WO | disclosed |